

# NEWS RELEASE

FOR IMMEDIATE RELEASE

November 8, 2018

## **Methapharm Inc. announces participation in Triumvira Immunologics Inc. Convertible Debenture**

Methapharm is pleased to announce that it has participated in a Private Placement of a Convertible Debenture of Triumvira Immunologics Inc.

### **About Methapharm**

Methapharm is a privately held specialty pharmaceutical company that focuses on the acquisition, licensing, and promotion of healthcare products in North America. Methapharm markets its own proprietary products, and partners with global companies to promote products in the USA and Canada. This investment accords with Methapharm's strategy to acquire marketed products, as well as invest in promising early-stage opportunities.

### **About Triumvira Immunologics**

Triumvira Immunologics, Inc. is an immuno-oncology company, developing a novel platform for engineering T cells to attack both liquid and solid tumors. Triumvira's proprietary T Cell-Antigen Coupler (TAC) co-opts the natural T Cell receptor biology and functions. This approach operates through the native T cell receptor, in turn optimizing selectivity and signaling, and has demonstrated superiority over CAR-T in pre-clinical studies. Led by a management team with decades of drug development expertise, Triumvira's pipeline includes multiple oncology trials slated to enter the clinic in 2019.

###

For more information about Methapharm or business development inquiries, please contact:

Craig Baxter  
President  
Tel: (+1) 519.751.3602 x7230

Chris Calenti  
Exec. Vice President (BD & Licensing)  
(+1) 519.751.3602 x7222